North American Prodromal Synucleinopathy (NAPS) Consortium

Overview

About this study

The purpose of this study is to establish a registry of RBD patients, develop quantitative biological and functional measures of synucleinopathy burden, and establish a formal process to evaluate candidate neuroprotective agents.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Idiopathic REM sleep behavior disorder diagnosis by ICSD-3 criteria confirmed by polysomnogram.
  • All participants must have polysomnogram-confirmed RBD by ICSD-3 criteria [AASM 2014].
  • 18 years of age or older.
  • Subject is sufficiently fluent in English to complete all measures.
  • Subject must be willing and able to consent to the protocol procedures.
  • Participants that phenoconvert will be eligible to continue participation in NAPS as long as they continue to have  the ability to provide informed consent. 

Exclusion Criteria:

  • Individuals who have a diagnosis of PD, dementia of any type, or MSA prior to consenting for NAPS.
  • Narcolepsy-associated RBD, which has a separate pathophysiological mechanism.
  • For Lumbar puncture only:
    • Anticoagulant medication or bleeding disorder;
    • Prior lumbar surgery or procedure that precludes LP.

 

 

 

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Alzheimer’s Disease Research Center

(507) 284-1324

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20438539

Mayo Clinic Footer